Editing Boston Scientific (section)

===Post-merger===
In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to [[Avista Capital Partners]].{{Sfn|Fluid Management & Venous Access, December 13,|2007}}

In April 2008, the company acquired CryoCor, Inc., for $1.35 per share, $17.6 million in total.{{Sfn|CryoCor, May 28,|2008}}{{Sfn|CryoCor Merger, April 16,|2008}} [[Navilyst Medical]] was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.{{Sfn|''Xconomy'', August 5,|2008|}}

In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.{{Sfn|Labcoat Ltd., January 6,|2009}}

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others.{{Sfn|''Seattle Times'', August 13,|2011|p=}} In the same month Boston Scientific acquired Asthmatx, Inc., for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.{{Sfn|Asthmatx, October 26,|2010}}

In January 2011, Boston acquired Atritech, Inc., for $100 million plus additional potential payments of up to $275 million.{{sfn|Ford, July 22,|2020}} Atritech developed a novel device called the Watchman® designed to close the left atrial appendage in patients with atrial fibrillation who are at risk for ischemic stroke.{{Sfn|Atritech, January 19,|2011}} In the same month, Boston Scientific acquired Intelect Medical, Inc., for $78 million{{Sfn|Intelect Medical, January 5,|2011}} and the remaining 86% of Sadra Medical, Inc., not already owned for $193 million plus contingent payments.{{Sfn|Sadra Medical, January 4,|2011}} At the same time, the business divested its neurovascular business to [[Stryker Corporation]] for $1.5 billion.{{Sfn|Neurovascular business, January 3,|2011}}

In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved.{{Sfn|Cameron Health, June 8,|2012}} In September the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions.{{Sfn|BridgePoint Medical, September 19,|2012}} In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures.{{Sfn|Rhythmia Medical, October 8,|2012}}  A month later the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc.{{Sfn|Vessix Vascular, November 8,|2012}}

In November 2013, Boston announced it would acquire Bard EP, the [[electrophysiology]] business of [[C.R. Bard, Inc.]],{{Sfn|Bard Electrophysiology, November 1,|2013}} for $275 million.{{Sfn|C.R. Bard Electrophysiology, June 28,|2013}}

In May 2014, Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc.{{Sfn|IoGyn, May 6,|2014}} In September, the business announced it would acquire the Interventional business of [[Bayer]].{{Sfn|Bayer Interventional Business, September 2,|2014}}

In March 2015, the company announced it would acquire [[Endo International|Endo International Plc]]'s American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments.{{Sfn|''Bloomberg News'', March 2,|2015}} In April, Boston announced its intention to acquire Xlumena, Inc.{{Sfn|Xlumena, April 1,|2015}} In October Boston announced it had invested further in percutaneous [[mitral valve replacement]] system developer, MValve Technologies, gaining a right to acquire the business in the future.{{Sfn|MValve Technologies, October 8,|2015}}

As of 2016, it operates in more than 100 countries, employs more than 24,000 people, and manufactures around 13,000 diverse products.{{Sfn|''Market Realist'', May 13,|2016}} In July 2016 the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc.{{Sfn|Cosman Medical, July 27,|2016}} In September, Boston announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $8.00 per share or $210 million in total.{{Sfn|EndoChoice, November 22,|2016}}{{Sfn|''MassDevice'', August 27,|2016}} In November the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices.{{Sfn|Resectr™ Tissue Resection Device, November 15,|2016}} In December 2016, the business acquired a 15% stake in Neovasc, Inc., for $75 million.{{Sfn|Neovasc Advanced Biological Tissue, December 12,|2016}}

In May 2017, the company acquired Symetis SA, a developer of minimally invasive [[transcatheter aortic valve implantation]] devices.{{Sfn|Symetis, May 16,|2017}} In October Boston acquired Apama Medical Inc. for up to $300 million.{{Sfn|Apama Medical, October 2,|2017}}

In April 2018, Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation,{{Sfn|nVision Medical, April 16,|2018}} NxThera{{Sfn|NxThera, April 30,|2018}} and Securus Medical Group, Inc., for up to $50 million.{{Sfn|Securus Medical Group, April 3,|2018}} In July, Boston Scientific announced it would acquire Cryterion Medical, Inc,{{Sfn|Cryterion Medical, July 5,|2018}} Veniti, Inc.,{{Sfn|VENITI, August 8,|2018}} in August Augmenix, Inc., and Claret Medical, Inc.{{Sfn|Claret Medical, August 2,|2018}} and in October{{Sfn|Augmenix, October 16,|2018}} In late November Boston announce they would acquire UK medical device maker, [[BTG plc]], for $4.2 billion.{{Sfn|Keown, November 20,|2018}} BTG, before being acquired, was publicly traded and a constituent of the [[FTSE 250 Index]]. In late December, the company announced it would acquire Millipede, Inc for $325 million – after previously investing $90 million in the company.{{Sfn|Terry, December 28,|2018}}
{{Portal|Companies}}

In May 2019, the company announced it would acquire Vertiflex, Inc., with the aim of increasing its interventional pain therapy offerings. Vertiflex principally developed treatment for [[lumbar spinal stenosis]].{{Sfn|Vertiflex, May 9,|2019}}

In January 2021, Boston announced it would acquire Minneapolis-based Preventice Solutions, Inc., and its portfolio of mobile cardiac health solutions for up to $1.2 billion.{{Sfn|Preventice Solutions, January 21,|2021}} In March, the business announced it would acquire Lumenis Ltd. for $1 billion from an affiliate of [[Baring Private Equity Asia]],{{Sfn|Lumenis Surgical Business, March 3,|2021}} who, in 2019, had acquired it from XIO Group.{{Sfn|''NS Medical Devices'', November 20,|2019}} In June, the company announced it would acquire the 73% of Farapulse, Inc., it did not already own, for $295 million. Farapulse was a [[University of Iowa]] [[Startup company|startup]]. The deal complimented Boston Scientific's existing electrophysiology portfolio.{{Sfn|Farapulse, June 24,|2021}} In September, the business announced it would acquire Devoro Medical, Inc., and its blood clot capturing technology.{{Sfn|Devoro Medical, September 21,|2021}} Boston Scientific had been a strategic investor in Devoro since 2019. In October, the company announced it would acquire Baylis Medical Company Inc. for $1.75 billion, expanding its electrophysiology and heart product portfolios (see [[Frank Baylis]]).{{Sfn|''Reuters'', October 6,|2021}}{{Sfn|''Globe and Mail'', October 6,|2021}}

In June 2022, the business announced it would acquire M.I.Tech Co., Ltd., of South Korea, for around $230 million.{{Sfn|M.I.Tech Co., June 15,|2022}} The deal was cancelled in May 2023 citing regulatory hurdles.{{Sfn|''Fierce Biotech'', May 25,|2023}} In August, Boston announced it would acquire Obsidio, Inc.{{Sfn|Obsidio, August 15,|2022}}

In September 2023, Boston Scientific acquired Relievant Medsystems, Inc. for an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.<ref>{{Cite press release |last= |first= |title=Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc. |url=https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-relievant-medsystems-inc-301931674.html |access-date=2023-09-19 |website=www.prnewswire.com |language=en |archive-date=September 20, 2023 |archive-url=https://web.archive.org/web/20230920213420/https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-relievant-medsystems-inc-301931674.html |url-status=live }}</ref>

In January 2024, the company announced it would acquire [[Axonics, Inc.]] for $3.7 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/boston-scientific-announces-agreement-to-acquire-axonics-inc-/?s=79 | title=Boston Scientific Announces Agreement to Acquire Axonics, Inc | date=January 8, 2024 | access-date=January 11, 2024 | archive-date=June 1, 2024 | archive-url=https://web.archive.org/web/20240601135109/https://www.biospace.com/article/releases/boston-scientific-announces-agreement-to-acquire-axonics-inc-/?s=79 | url-status=live }}</ref>

{{hidden begin|border=1px  #aaa solid|title=Boston Scientific mergers & acquisitions|ta1=center}}
{{Tree list}}
*'''Boston Scientific'''
**Precision Vascular Systems, Inc. <small>(Acq 2004)</small>
**Advanced Bionics Corporation <small>(Acq 2004)</small>
**Advanced Stent Technologies, Inc. <small>(Acq 2004)</small>
**TriVascular, Inc. <small>(Acq 2005)</small>
**CryoVascular Systems, Inc. <small>(Acq 2005)</small>
**Nemo I Acquisition, Inc.
***Rubicon Medical Corporation <small>(Acq 2005)</small>
**[[Guidant]] <small>(Acq 2006 and split between Boston and [[Abbott Laboratories]])</small>
**CryoCor, Inc. <small>(Acq 2008)</small>
**Labcoat Limited <small>(Acq 2009)</small>
**Asthmatx, Inc. <small>(Acq 2010)</small>
**Atritech, Inc. <small>(Acq 2011)</small>
**Intelect Medical, Inc. <small>(Acq 2011)</small>
**Sadra Medical, Inc. <small>(Acq 2011)</small>
**Cameron Health <small>(Acq 2012)</small>
**BridgePoint Medical, Inc. <small>(Acq 2012)</small>
**Rhythmia Medical, Inc. <small>(Acq 2012)</small>
**Vessix Vascular, Inc. <small>(Acq 2012)</small>
**Bard EP <small>(Acq 2013)</small>
**IoGyn, Inc. <small>(Acq 2014)</small>
**[[Bayer]] <small>(Interventional business, Acq 2014)</small>
**[[Endo International]] <small>(Urology business, Acq 2015)</small>
**Xlumena, Inc. <small>(Acq 2015)</small>
**Cosman Medical, Inc. <small>(Acq 2016)</small>
**EndoChoice Holdings, Inc. <small>(Acq 2016)</small>
**Distal Access, LLC <small>(Gynecology and Urology business, Acq 2016)</small>
**Symetis SA <small>(Acq 2017)</small>
**Apama Medical Inc. <small>(Acq 2017)</small>
**nVision Medical Corporation <small>(Acq 2018)</small>
**NxThera <small>(Acq 2018)</small>
**Securus Medical Group, Inc. <small>(Acq 2018)</small>
**Cryterion Medical, Inc. <small>(Acq 2018)</small>
**Veniti, Inc. <small>(Acq 2018)</small>
**Augmenix, Inc. <small>(Acq 2018)</small>
**Claret Medical, Inc. <small>(Acq 2018)</small>
**[[BTG plc]] <small>(Acq 2018)</small>
***British Technology Group <small>(Merged 1981)</small>
****[[National Research Development Corporation]] (NRDC) <small>(Est. 1948)</small>
****[[National Enterprise Board]] (NEB) <small>(Est. 1975)</small>
***Protherics Plc <small>(Acq 2008)</small>
***[[Biocompatibles]] <small>(Acq 2011)</small>
***Galil Medical <small>(Acq 2016)</small>
***Novate Medical <small>(Acq 2018)</small>
**Millipede, Inc. <small>(Acq 2018)</small>
**Vertiflex, Inc. <small>(Acq 2019)</small>
**Preventice Solutions, Inc. <small>(Acq 2021)</small>
**Lumenis Ltd <small>(Acq 2021)</small>
**Farapulse, Inc <small>(Acq 2021)</small>
**Devoro Medical, Inc. <small>(Acq 2021)</small>
**Baylis Medical Company Inc <small>(Acq 2021)</small>
**Obsidio <small>(Acq 2022)</small>
**Relievant Medsystems, Inc. <small>(Acq 2023)</small>
**Apollo Endosurgery, Inc <small>(Acq 2023)</small>
**Axonics, Inc. <small>(Acq 2024)</small>
**SoniVie Ltd <small>(Acq 2025)</small>
{{Tree list/end}}
{{hidden end}}